CMV (Cytomegalovirus)



Biomarkers of Cytomegalovirus Fetal Infection and Disease


Condition:   Cytomegalovirus Congenital
Intervention:   Biological: Bio-specimen collected
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified March 2017


Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients


Condition:   Cytomegalovirus (CMV)
Interventions:   Drug: Maribavir;   Drug: Valganciclovir;   Drug: Placebo
Sponsor:   Shire
Recruiting - verified April 2017


Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment


Condition:   Cytomegalovirus (CMV)
Interventions:   Drug: Maribavir;   Drug: Investigator-Assigned Treatment
Sponsor:   Shire
Recruiting - verified February 2017


Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults


Condition:   Cytomegalovirus Infections
Interventions:   Drug: VBI-1501A;   Drug: VBI-1501A;   Drug: VBI-1501A;   Drug: VBI-1501;   Drug: Placebo
Sponsors:   VBI Vaccines Inc.;   Clinical Trial Data Services, LLC;   Virginia Commonwealth University
Recruiting - verified July 2016


Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV


Condition:   Cytomegalovirus Infection
Interventions:   Biological: Low dose HB-101;   Biological: Medium dose HB-101;   Biological: High dose HB-101;   Biological: Placebo
Sponsors:   Hookipa Biotech;   Centre for Vaccinology Ghent - CEVAC
Active, not recruiting - verified June 2016


Screening for Congenital Cytomegalovirus Infection in Newborns


Condition:   Cytomegalovirus Infections
Intervention:   Other: Observation
Sponsors:   Southern Illinois University;   University of Alabama at Birmingham
Enrolling by invitation - verified April 2017


Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence


Condition:   Cytomegalovirus Infections
Interventions:   Drug: Drug conversion to sirolimus;   Drug: Maintenance of the current regimen
Sponsor:   Hospital do Rim e Hipertensão
Recruiting - verified August 2016


The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University


Condition:   Cytomegalovirus Infections
Intervention:  
Sponsor:   Jun Zhang
Completed - verified December 2015


Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine


Condition:   Congenital Cytomegalovirus Infection
Intervention:   Drug: CyMVectin
Sponsors:   Virginia Commonwealth University;   Vical
Withdrawn - verified September 2016


Cell-mediated Immunity for Prevention of CMV Disease


Condition:   Cytomegalovirus Infections
Intervention:   Other: T-Track® CMV assay
Sponsor:   University of Lausanne Hospitals
Recruiting - verified November 2016


A Cohort Study of Cytomegalovirus(CMV) Infection Among Pregnant Women and Their Newborns in China


Conditions:   Congenital Cytomegalovirus Infection;   Cytomegalovirus Infection Reactivation
Intervention:  
Sponsors:   Jun Zhang;   Merck Sharp & Dohme Corp.;   National Natural Science Foundation of China
Recruiting - verified April 2017


SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients


Condition:   Cytomegalovirus Disease
Interventions:   Drug: Brincidofovir;   Drug: Valganciclovir
Sponsor:   Chimerix
Terminated - verified January 2017


Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy


Condition:   Congenital Cytomegalovirus Infection
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsor:   Rabin Medical Center
Recruiting - verified April 2017


MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)


Condition:   Cytomegalovirus Infections
Interventions:   Drug: MK-8228;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified December 2016


Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive


Condition:   Cytomegalovirus Infections
Intervention:  
Sponsors:   Fundacio Catalana de Pneumologia;   Roche Farma, S.A
Completed - verified September 2016


Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)


Condition:   Cytomegalovirus Infections
Interventions:   Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor


Condition:   Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions:   Biological: ASP0113;   Drug: Placebo
Sponsors:   Astellas Pharma Global Development, Inc.;   Vical
Active, not recruiting - verified April 2017


Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero


Condition:   Congenital Cytomegalovirus Infection
Intervention:   Other: Standardized test report
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified December 2016


A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients


Condition:   Cytomegalovirus Infections
Interventions:   Drug: MCMV3068A;   Drug: MCMV5322A;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed - verified March 2017


A Study in Adolescent Females to Explore Cytomegalovirus Infection


Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood collection;   Procedure: Urine collection;   Procedure: Saliva collection
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified January 2017


Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus


Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood sample;   Procedure: Cord blood sample;   Procedure: Saliva swab;   Procedure: Urine sampling;   Procedure: Vaginal swab
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients


Condition:   Cytomegalovirus
Intervention:   Biological: depistage
Sponsor:   University Hospital, Limoges
Completed - verified September 2016


Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants


Condition:   Cytomegalovirus Infections
Intervention:   Biological: CMV-Peptide-Specific T cells
Sponsors:   Atara Biotherapeutics;   Memorial Sloan Kettering Cancer Center
Completed - verified February 2017


VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients


Condition:   Cytomegalovirus Infections
Interventions:   Drug: Ganciclovir;   Drug: valganciclovir [Valcyte]
Sponsor:   Hoffmann-La Roche
Completed - verified November 2016


Cytomegalovirus (CMV) Infection in Pregnancy


Conditions:   Pregnancy Complications;   Cytomegalovirus Infection
Intervention:  
Sponsor:   University of Pennsylvania
Completed - verified August 2016

Refine Your Search Advanced Search